---
canonical_name: Betaine
alternate_names: Trimethylglycine, TMG, Glycine betaine, Betaine anhydrous
canonical_topic: Betaine for Health & Longevity
short_topic_lc: betaine
creation_date: 2026-0723-0012
creator_ai_fullname: Grok 4
---

# Betaine for Health & Longevity
<section id="top" markdown="1"></section>
Evidence Review created on 07/23/2026 using [AI4L](https://github.com/forever-healthy/AI4L) / Grok 4

**Also known as:** Trimethylglycine, TMG, Glycine betaine, Betaine anhydrous


## Motivation

<!-- Motivation written last after all other sections were completed to capture full scope of the topic. -->

Betaine (also called trimethylglycine or TMG) is a naturally occurring compound found in foods such as beets, spinach, and whole grains, and made in the body from choline. It helps recycle the amino acid homocysteine into methionine by donating methyl groups, and it helps cells manage water balance under stress. Longevity-oriented adults often encounter it as a methyl-donor supplement, a training-support aid, or a companion to nicotinamide mononucleotide and related compounds.

Betaine anhydrous is also an approved prescription therapy for certain rare genetic disorders of homocysteine handling. Outside that setting, lower oral doses appear in studies of blood homocysteine and exercise strength, and in commercial products marketed for methylation support and performance. Interest has grown as people track methylation-related labs and seek practical tools that sit alongside diet, training, and B-vitamin status.

This review examines the human evidence for betaine as a health and longevity intervention—mechanisms, expected benefits and risks, who may respond differently, practical protocols, sourcing, monitoring, and emerging research—so that risk-aware adults can weigh the data without marketing spin.

**[Benefits](#expected-benefits) - [Risks](#potential-risks--side-effects) - [Protocol](#therapeutic-protocol) - [Conclusion](#conclusion)**


## Recommended Reading

High-level overviews and expert-facing discussions that introduce betaine’s methyl-donor role, performance data, and practical use.

<!-- Search performed July 2026: web and site searches for Rhonda Patrick/FoundMyFitness, Peter Attia, Andrew Huberman, Chris Kresser, and Life Extension for betaine/TMG/trimethylglycine; plus PubMed and general web for high-quality narrative reviews and practitioner articles. -->

* [Beneficial Effects of Betaine: A Comprehensive Review](https://pubmed.ncbi.nlm.nih.gov/34067313/) - Arumugam et al., 2021

  Narrative review of betaine as osmolyte and methyl donor, covering liver protection pathways, S-adenosylmethionine balance, inflammation, and non-hepatic effects—useful map of mechanisms before reading trial data.

* [How Can TMG Help Your Homocysteine Levels?](https://www.lifeextension.com/wellness/supplements/tmg-helps-homocysteine-levels) - Chancellor Faloon

  Accessible Life Extension overview of homocysteine as a cardiovascular and metabolic biomarker and how trimethylglycine supports remethylation alongside diet and B vitamins.

* [Why TMG (Betaine) is Exploding in Popularity](https://drstanfield.com/blogs/articles/tmg-betaine-exploding-popularity) - Brad Stanfield

  Clinician synthesis of exercise-performance and testosterone trial signals, dose context, and lipid safety trade-offs that often appear in longevity communities.

* [Betaine Supplementation Lowers Plasma Homocysteine](https://www.foundmyfitness.com/stories/5dydkx) - Rhonda Patrick / FoundMyFitness

  Brief FoundMyFitness science digest pointing to human evidence that supplemental betaine reduces circulating homocysteine—useful entry into Patrick’s broader one-carbon and homocysteine coverage.

* [TMG Supplement: Benefits, Dosage, Safety, and Use](https://www.bodyspec.com/blog/post/tmg_supplement_benefits_dosage_safety_and_use) - BodySpec

  Practical, biomarker-oriented summary distinguishing betaine anhydrous from betaine hydrochloride, with dose bands for homocysteine versus performance and a clear lipid-monitoring note.

No dedicated deep-dive episodes or articles focused on betaine/TMG were found from Peter Attia, Andrew Huberman, or Chris Kresser as of the search date; coverage on those platforms, when present, is incidental within broader choline, methylation, or cardiovascular discussions.


## Grokipedia

<!-- Direct search of grokipedia.com for betaine, trimethylglycine, and TMG (July 2026). Results returned chemistry/surfactant pages (e.g., mesomeric betaine, cocamidopropyl betaine) and unrelated product mentions; no dedicated health-or-longevity article on dietary or supplemental glycine betaine. -->

No Grokipedia article dedicated to betaine (trimethylglycine) as a dietary or longevity intervention was found as of July 2026.


## Examine

<!-- Direct search of examine.com for betaine / trimethylglycine (July 2026). Primary page located at examine.com/supplements/betaine/. -->

* [Betaine benefits, dosage, and side effects](https://examine.com/supplements/betaine/)

  Examine’s primary betaine page summarizes human evidence on homocysteine, exercise outcomes, body composition, and dose ranges, with a linked research breakdown—efficient cross-check against meta-analyses cited below.


## ConsumerLab

<!-- Direct search of consumerlab.com for betaine, TMG, and trimethylglycine (July 2026). Mentions of betaine hydrochloride appear in acid-reflux and digestive contexts; no dedicated product review or test report for betaine anhydrous / TMG as a methyl-donor supplement was identified. -->

No dedicated ConsumerLab product review for betaine anhydrous (TMG) was found as of July 2026. ConsumerLab content that mentions “betaine” typically refers to betaine hydrochloride for digestion, a distinct compound with a different use case.


## Systematic Reviews

Key systematic reviews and meta-analyses of supplemental or dietary betaine relevant to health, performance, and cardiovascular markers.

<!-- PubMed search July 2026: betaine OR trimethylglycine OR "glycine betaine" with systematic review OR meta-analysis filters; prioritized human supplementation outcomes, citation relevance, recency, and size. -->

* [Effects of chronic betaine supplementation on exercise performance: Systematic review and meta-analysis](https://pubmed.ncbi.nlm.nih.gov/39514262/) - Zawieja et al., 2024

  Seventeen trials (n ≈ 317) of chronic betaine versus placebo in healthy adults; significant effect on maximal strength (standardized mean difference ≈ 0.47), driven by lower-body strength, with a possible vertical-jump benefit after sensitivity analysis.

* [Effects of betaine supplementation on cardiovascular markers: A systematic review and Meta-analysis](https://pubmed.ncbi.nlm.nih.gov/33764214/) - Ashtary-Larky et al., 2022

  Pooled randomized trials showing reduced homocysteine (~1.3 µmol/L) alongside dose-dependent increases in total and low-density lipoprotein (LDL) cholesterol at higher intakes; authors favor doses under 4 g/day for homocysteine lowering without the lipid rise seen at ≥4 g/day.

* [Betaine supplementation fails to improve body composition: a systematic review and meta-analysis](https://pubmed.ncbi.nlm.nih.gov/34743773/) - Ashtary-Larky et al., 2022

  Meta-analysis finding no significant effects on body mass, body mass index (BMI), fat mass, fat-free mass, or body-fat percentage across available randomized controlled trials (RCTs), contradicting more optimistic fat-loss summaries.

* [Betaine Supplementation Moderately Increases Total Cholesterol Levels: A Systematic Review and Meta-Analysis](https://pubmed.ncbi.nlm.nih.gov/31809615/) - Zawieja et al., 2021

  Six RCTs of ≥4 g/day for ≥6 weeks; pooled increase in total cholesterol of about 0.34 mmol/L (~13 mg/dL), with non-significant effects on LDL, high-density lipoprotein (HDL), and triglycerides in that dose band.

* [Effect of Betaine on Reducing Body Fat-A Systematic Review and Meta-Analysis of Randomized Controlled Trials](https://pubmed.ncbi.nlm.nih.gov/31623137/) - Gao et al., 2019

  Earlier meta-analysis of six RCTs reporting reductions in fat mass (~2.5 kg) and body-fat percentage (~2.4%) without significant weight change—results that later, larger body-composition syntheses did not confirm.


## Mechanism of Action

Betaine (N,N,N-trimethylglycine) is a zwitterionic quaternary ammonium compound obtained from diet or synthesized by oxidation of choline. Two primary physiologic roles dominate human biology:

* **Methyl donation (one-carbon metabolism):** In the liver and kidney, the enzyme betaine-homocysteine S-methyltransferase (BHMT) transfers a methyl group from betaine to homocysteine, forming methionine and dimethylglycine (DMG). Methionine feeds production of S-adenosylmethionine (SAM), the universal methyl donor for DNA, protein, and phospholipid methylation. This BHMT route runs in parallel with the folate- and vitamin B12–dependent methionine synthase path; when folate/B12 flux is limited or methionine load is high, the BHMT path becomes more important for clearing homocysteine.

* **Osmoprotection:** Betaine accumulates in cells under osmotic or chemical stress, stabilizing proteins and membranes and helping maintain cell volume—relevant in kidney medulla, liver, and muscle under training stress.

Secondary proposed effects include support of creatine synthesis (via methionine/SAM supply), modest influence on nitric oxide–related blood flow, improved cellular hydration during high-intensity work, and modulation of inflammatory and oxidative pathways in animal and cell models. Human evidence is strongest for the homocysteine–methionine axis; performance and body-composition claims rest on weaker, more context-dependent signals.

**Pharmacologic properties (oral anhydrous betaine):**

* **Absorption:** Rapid; peak plasma levels typically within about 1 hour after oral dosing.
* **Distribution:** Widely distributed; high tissue retention as an intracellular osmolyte.
* **Metabolism:** Primarily metabolic conversion to DMG (then sarcosine/glycine) rather than renal excretion of intact betaine; urinary recovery of unchanged betaine is low in healthy adults (~4% of dose in kinetic studies).
* **Half-life:** Single-dose elimination half-life on the order of ~14 hours in healthy subjects; with repeated dosing, apparent half-life lengthens (reported ~40 hours range) as tissue pools expand.
* **Selectivity:** Not a receptor drug; acts as substrate for BHMT and as an osmolyte. Distinct from betaine hydrochloride, which is used only as a gastric acidifier and is not interchangeable for methylation goals.


## Historical Context & Evolution

Betaine was first isolated from sugar beets (*Beta vulgaris*) in the 19th century, which is the origin of the name. Industrial interest grew with beet sugar processing; medically, betaine anhydrous later became a recognized treatment for homocystinuria and related inborn errors of methionine metabolism, where large daily doses reduce pathological hyperhomocysteinemia. In the United States, prescription betaine anhydrous (historically marketed as Cystadane) is indicated for that genetic indication.

From the 1990s onward, rising interest in plasma total homocysteine as a cardiovascular risk marker led researchers to test lower oral doses (typically 1.5–6 g/day) in people without rare genetic disease. Trials consistently showed homocysteine reductions, but large B-vitamin outcome trials later cast doubt on whether lowering homocysteine with vitamins reliably reduces cardiovascular events—leaving betaine’s biomarker effect solid and its hard-outcome role unproven. Concurrently, animal work on fatty liver and human pilot studies motivated a multi-year randomized trial of high-dose betaine in nonalcoholic steatohepatitis, which did not improve primary histology endpoints relative to placebo. Sports-nutrition research explored 2–2.5 g/day for strength and power, with mixed early results and more supportive meta-analytic signals for lower-body strength by the mid-2020s. Longevity communities adopted TMG as a methyl-donor stack component (often with nicotinamide mononucleotide or B vitamins), extrapolating from methylation and homocysteine biology more than from aging-specific RCTs.


## Expected Benefits

### High 🟩 🟩 🟩

#### Lowering of plasma total homocysteine

Betaine donates a methyl group via BHMT to convert homocysteine to methionine. Multiple randomized trials and a cardiovascular-marker meta-analysis show reliable reductions in circulating total homocysteine in adults with and without elevated baseline levels. The effect is a biomarker change; large outcome trials of other homocysteine-lowering regimens have not consistently translated similar biomarker shifts into fewer cardiovascular events, so clinical event benefit remains uncertain even when the lab value improves.

**Magnitude:** Meta-analytic weighted mean reduction on the order of ~1.3 µmol/L; individual trials often report larger absolute drops when baseline homocysteine is higher or doses are several grams daily.


### Medium 🟩 🟩

#### Improvement in maximal muscular strength (especially lower body) with training

A 2024 systematic review and meta-analysis of chronic betaine supplementation (typically ≥7 days) in healthy adults found a moderate standardized effect on maximal strength measures (one-repetition maximum, multi-rep max, or maximal force), concentrated in lower-body exercises. Upper-body strength, cycling sprint power, and muscular endurance signals were weaker or non-significant. Proposed mechanisms include creatine synthesis support, cellular hydration, and training-quality effects rather than a pure hypertrophy driver.

**Magnitude:** Standardized mean difference ≈ 0.47 for maximal strength overall; lower-body standardized mean difference (SMD) ≈ 0.49 (95% confidence interval (CI) roughly 0.01–0.98). Absolute kg gains vary by study and training status.

#### Dose-dependent support of methionine/SAM pool dynamics under methyl stress

By accelerating BHMT flux, betaine raises dimethylglycine and can support methionine availability when one-carbon demand is high (high methionine meals, low folate/B12, genetic remethylation constraints). This is well documented biochemically and in kinetic trials; longevity relevance is inferred from methylation biology rather than from aging-endpoint RCTs.

**Magnitude:** Not quantified in available studies as a single clinical “methylation score”; plasma betaine and DMG rise substantially (e.g., multi-fold plasma betaine increases at multi-gram doses).


### Low 🟩

#### Possible vertical jump / power transfer under selected protocols

After excluding a low-quality study, the 2024 performance meta-analysis reported a small improvement in vertical jump. Effects on other power metrics (bench-press throw power, Wingate) were not consistently significant across trials. Benefits appear context-dependent on training type and athlete status.

**Magnitude:** Standardized mean difference ≈ 0.36 for vertical jump in the sensitivity analysis; not robust across all power outcomes.

#### Limited signals for inflammatory cytokine change

A meta-analysis of RCTs found a small reduction in circulating interleukin-1β with high heterogeneity and no clear effects on C-reactive protein, interleukin-6, or tumor necrosis factor-α. Evidence is insufficient to claim a reliable anti-inflammatory benefit in generally healthy adults.

**Magnitude:** IL-1β pooled change ≈ −0.65 pg/mL (highly heterogeneous); other markers not significantly changed.


### Speculative 🟨

#### Body-fat reduction independent of diet and training ⚠️ Conflicted

An earlier meta-analysis (Gao et al., 2019) reported meaningful fat-mass and body-fat-percentage reductions without weight change, while a later synthesis (Ashtary-Larky et al., 2022) found no significant effects on body mass, fat mass, fat-free mass, or body-fat percentage. Method differences, small samples, and possible hydration-related measurement noise (betaine is an osmolyte) likely contribute. Body-composition benefit should not be assumed.

#### Liver-fat or nonalcoholic steatohepatitis (NASH) tissue improvement

Animal models and early human pilot work motivated use in nonalcoholic fatty liver disease. The pivotal randomized placebo-controlled trial of 20 g/day betaine for 12 months in biopsy-proven NASH did not improve the primary nonalcoholic fatty liver disease activity score or fibrosis versus placebo, though steatosis grade improved within the betaine arm and may have been protected from worsening. Ongoing trials in metabolic dysfunction–associated steatohepatitis may revise this picture.

#### Cognitive or neurodegenerative protection via homocysteine and methylation

Mechanistic and limited experimental work links lower homocysteine and better methylation capacity to brain aging pathways. Human evidence that supplemental betaine improves cognition or delays dementia is not established; any effect would currently be extrapolated from biomarker and animal data.


## Benefit-Modifying Factors

* **Baseline homocysteine:** Larger absolute reductions tend to occur when baseline total homocysteine is elevated; already-low values leave less room for change.
* **MTHFR (methylenetetrahydrofolate reductase, a folate-pathway remethylation enzyme) and related one-carbon genetics:** Variants that impair folate-dependent remethylation (e.g., common MTHFR polymorphisms) can increase reliance on the BHMT/betaine path; folate/B12 status still matters and should be optimized in parallel.
* **Choline intake and status:** Low dietary choline may increase dependence on supplemental betaine for methyl balance; high choline already supplies endogenous betaine after oxidation.
* **Training stimulus:** Strength benefits in meta-analyses are seen in the context of resistance or high-intensity work; passive use without training is unlikely to produce performance gains.
* **Sex:** Performance literature includes fewer women than men; some trials in active young women show mixed body-composition and anaerobic results—sex-specific effect sizes remain under-defined.
* **Age:** Older adults may care most about strength preservation and homocysteine, but dedicated large RCTs in older longevity-seeking populations are sparse; pharmacokinetics may change with kidney function.
* **Metabolic and liver disease:** Insulin resistance, obesity, and fatty liver alter one-carbon fluxes; high-dose NASH RCT results caution against assuming histologic liver benefit from betaine alone.
* **Concurrent methyl donors and B vitamins:** Folate, B12, B6, and creatine change methyl demand and homocysteine pathways; stacked use can amplify biomarker shifts and complicates attribution.


## Potential Risks & Side Effects

### High 🟥 🟥 🟥

#### Gastrointestinal intolerance at higher doses

Nausea, diarrhea, dyspepsia, and bloating are the most commonly reported adverse effects of oral betaine anhydrous, especially as daily intake rises into multi-gram and double-digit gram ranges used in genetic disease and some liver trials. Effects are usually dose-related and improve with dose reduction, splitting doses, or taking with food.

**Magnitude:** Frequent enough at high therapeutic doses (e.g., tens of grams/day in labeled genetic indications) that labeling and clinical practice emphasize gastrointestinal (GI) monitoring; at 1.5–3 g/day GI events are less common but still reported.


### Medium 🟥 🟥

#### Increase in total and/or LDL cholesterol at higher supplemental doses

Meta-analyses of RCTs show that betaine, particularly at ≥4 g/day for weeks to months, can raise total cholesterol (on the order of ~10–14 mg/dL in pooled estimates) and LDL cholesterol in several analyses. Subgroup interpretation in cardiovascular-marker meta-analysis suggests homocysteine lowering may be achievable below 4 g/day with less lipid impact. The clinical significance for long-term cardiovascular risk is not settled, but the biomarker shift is reproducible enough to warrant lipid monitoring in longevity users.

**Magnitude:** Total cholesterol (TC) increase ≈ 0.34 mmol/L (~13 mg/dL) in ≥4 g/day meta-analysis; cardiovascular-marker meta-analysis reported TC mean difference ≈ +14 mg/dL and LDL mean difference ≈ +10 mg/dL across included doses, with dose-stratified caution at ≥4 g/day.

#### Elevated plasma dimethylglycine and related metabolites

Betaine metabolism predictably raises DMG. DMG itself is generally considered a pathway intermediate rather than a classic toxin, but large metabolite shifts indicate substantial pathway engagement and are a reminder that “more methyl donor” is not metabolically neutral.

**Magnitude:** Meta-analytic DMG increase on the order of ~20 µmol/L class effects in cardiovascular-marker synthesis; individual kinetic studies show clear post-dose DMG rises and accumulation with multi-day dosing.


### Low 🟥

#### Fishy body odor or trimethylamine-related odor (uncommon)

As with other trimethylamine-containing compounds, rare individuals report body or urine odor changes, possibly related to microbial or metabolic conversion pathways. Distinct from the more discussed trimethylamine N-oxide (TMAO) pathway concern (see Speculative).

**Magnitude:** Not quantified in available studies.

#### Central nervous system symptoms at very high therapeutic doses

Prescription labeling and drug references for betaine anhydrous used in genetic disorders list less common but serious events including confusion, drowsiness, behavior changes, headache, and rarely seizures. These reports cluster at multi-gram to tens-of-grams daily regimens under specialist care rather than the elective 1–3 g/day band common in longevity use; they remain relevant when high-dose protocols are considered.

**Magnitude:** Not quantified in available studies.


### Speculative 🟨

#### Trimethylamine N-oxide (TMAO) pathway concern

Gut microbes can generate trimethylamine from certain choline/betaine-related substrates, which the liver oxidizes to TMAO—a metabolite linked observationally to cardiovascular disease (CVD) risk. Direct evidence that standard oral betaine anhydrous doses meaningfully raise TMAO in humans is limited and mixed; some acute-intake work has not shown large TMAO jumps from betaine alone. Observational links between circulating choline (and sometimes betaine) and CVD risk further complicate interpretation without proving causation from supplements.

#### Over-methylation symptoms (subjective)

Anecdotal reports in methylation-supplement communities describe anxiety, insomnia, or agitation when combining multiple methyl donors. Controlled evidence specific to betaine is lacking; if such symptoms occur, they are managed empirically by dose reduction or simplifying multi-supplement regimens.

#### Theoretical interaction with aggressive multi-methyl-donor longevity combinations

Combining high-dose betaine with nicotinamide mononucleotide, methylfolate, methylcobalamin, and creatine multiplies pathway inputs. Long-term safety of such combinations is not established in large trials.


## Risk-Modifying Factors

* **Dose band:** Lipid and GI risks rise more clearly at ≥4 g/day and at prescription-scale doses; many longevity and performance users stay near 1–3 g/day.
* **Baseline lipids:** Pre-existing hyperlipidemia may amplify concern about further LDL/TC increases—baseline and follow-up lipid panels matter more in this group.
* **Kidney function:** Betaine handling and metabolite clearance involve renal pathways; reduced estimated glomerular filtration rate (eGFR) warrants caution and medical oversight for high doses.
* **Homocystinuria / severe genetic disorders:** Different risk–benefit calculus under specialist care with approved high-dose regimens—not the same as elective longevity use.
* **Age:** Older adults more often have polypharmacy, chronic kidney disease (CKD), and atherosclerotic disease—monitor lipids and renal function more closely.
* **Sex:** Sex-specific adverse-event rates are not well characterized; pregnancy and lactation require separate caution (see contraindications).
* **Gut microbiome composition:** May influence any TMAO-related signal from trimethyl substrates; not currently actionable via routine testing for betaine decisions.
* **Concurrent lipid-raising or lipid-lowering therapy:** Stacking with other agents that affect LDL complicates attribution and monitoring cadence.


## Key Interactions & Contraindications

* **Other methyl donors and B vitamins (folate/methylfolate, vitamin B12, vitamin B6, choline, creatine):** Severity: monitor / generally compatible. Additive effects on homocysteine and one-carbon flux; can mask B12 deficiency if only homocysteine is watched without methylmalonic acid or B12 levels. Mitigate by measuring B12/folate status and avoiding redundant mega-doses without indication.
* **Nicotinamide mononucleotide (NMN) / nicotinamide riboside stacks:** Severity: caution (theoretical). Popular longevity pairing (TMG “to support methylation” during nicotinamide adenine dinucleotide (NAD+) precursor use) lacks large outcome trials; watch for subjective overstimulation and check lipids/homocysteine.
* **Lipid-lowering therapy (statins such as atorvastatin, rosuvastatin; ezetimibe; proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors):** Severity: monitor. Betaine-related LDL/TC increases could partially offset therapy goals—recheck lipids after dose changes.
* **Antihypertensives and metabolic drugs:** Severity: low / monitor as usual. No consistent large effect of betaine on blood pressure (BP) or glucose in meta-analysis, but individual responses vary.
* **Methotrexate and other antifolate or one-carbon–active drugs:** Severity: caution. Pathway overlap is biologically plausible; coordinate with the prescribing clinician.
* **Betaine hydrochloride products:** Severity: confusion risk, not a true drug–drug interaction. Betaine HCl is not a substitute for TMG methylation goals and may irritate the stomach.
* **Populations who should avoid or use only under specialist care:**
  * Known allergy to betaine anhydrous.
  * Pregnancy and breastfeeding outside medical indication (insufficient elective-use safety data at supplemental doses; prescription use only under specialist guidance).
  * Children except for approved metabolic-disease protocols.
  * Severe renal impairment without specialist dosing (threshold: advanced CKD / dialysis—avoid self-directed multi-gram use).
  * Active peptic ulcer disease if mistakenly using betaine HCl rather than anhydrous TMG.


## Risk Mitigation Strategies

* **Stay in a lower dose band when lipids are a concern:** Prefer ~1–3 g/day (often 1.5–2.5 g for performance literature; ≤3 g when primary goal is modest homocysteine support) rather than ≥4 g/day if lipid elevation is unacceptable. This targets the dose region meta-analyses associate with less cholesterol rise.
* **Split doses and take with food:** Divide total daily amount into 2 doses to reduce GI intolerance and smooth plasma peaks.
* **Baseline and follow-up lipid panel:** Check fasting lipid panel before starting and again at 6–12 weeks after a stable dose—mitigates unnoticed LDL/TC creep.
* **Homocysteine plus B-status labs:** Measure total homocysteine with folate and B12 (and methylmalonic acid when B12 status is unclear) so methyl-donor use does not obscure deficiency.
* **Simplify multi-supplement regimens:** Add betaine alone before combining with NMN, high-dose methylfolate, and multiple other methyl donors—reduces attribution problems and subjective overstimulation risk.
* **Choose anhydrous TMG, not HCl, for methylation goals:** Avoid accidental gastric irritation and wrong-compound use.
* **Hydration and training-aware use:** Because betaine is an osmolyte, maintain normal fluid intake during heavy training blocks; do not interpret short-term scale weight changes as fat gain alone.
* **Medical oversight for high-dose or disease-directed use:** Doses approaching those in NASH or genetic-disease protocols belong under clinician supervision with labs.


## Therapeutic Protocol

* **Common longevity / general health dose:** 500 mg–2 g once or twice daily of betaine anhydrous (TMG), often totaling 1–3 g/day—aligned with lower-dose homocysteine studies and many commercial products. Some longevity practitioners discuss 500 mg–1 g/day as a conservative multi-supplement component (e.g., alongside NAD+ precursors); others use ~1.5–2.5 g/day when strength outcomes are also of interest.
* **Performance-oriented dose:** Trials and meta-analyses frequently use about 2–2.5 g/day for ≥1–2 weeks alongside structured resistance or mixed training; chronic use of at least 7 days is the frame used in the 2024 performance meta-analysis.
* **Homocysteine-focused dose:** 1.5–6 g/day appears in clinical nutrition trials; cardiovascular-marker meta-analysis discussion favors staying under 4 g/day when possible to limit lipid effects while still lowering homocysteine.
* **Prescription genetic-disease dosing:** Far higher (multi-gram, often weight-based, divided doses) under metabolic specialists—not a template for elective longevity use.
* **Time of day:** No strict chronobiology requirement. Many users take it morning and/or pre-training; evening dosing is acceptable if it does not subjectively disturb sleep when stacked with other stimulants or methyl donors.
* **Half-life and splitting:** Single-dose half-life ~14 hours with lengthening on chronic dosing supports once- or twice-daily schedules; split dosing is preferred above ~2 g/day for GI comfort.
* **Form:** Betaine anhydrous (powder or capsules). Do not substitute betaine HCl for methylation aims.
* **Genetics:** Consider MTHFR and related one-carbon variants as context for why BHMT support might matter, not as a mandate for high-dose TMG. Optimize folate and B12 first when deficiency is present.
* **Sex and age:** No validated sex-specific dose table; older adults should start low (e.g., 500 mg–1 g/day), recheck lipids and renal function, and avoid aggressive self-directed escalation.
* **Baseline biomarkers:** Elevated homocysteine, low choline intake, and high training load are practical reasons people trial betaine; normal homocysteine and sedentary lifestyle predict less noticeable benefit.
* **Conditions:** Fatty liver interest should be tempered by the negative primary endpoints of the high-dose NASH RCT; metabolic disease management remains diet, weight, and guideline therapies first.


## Discontinuation & Cycling

* **Duration of use:** Elective use is often continuous for biomarker or stack goals rather than a defined short course; performance trials last weeks to a few months. Lifelong necessity is not established outside genetic indications.
* **Withdrawal effects:** No classic withdrawal syndrome is described. Plasma betaine and DMG fall after stopping as pools clear over days; homocysteine may drift back toward baseline if diet and B-vitamin status are unchanged.
* **Tapering:** Not required for pharmacologic dependence; stepping down can help separate betaine’s effect from other stack changes when evaluating labs.
* **Cycling:** No strong evidence that cycling preserves efficacy. Some users cycle only because they cycle companion supplements (e.g., NMN). Continuous low-dose use with periodic labs is a common practical pattern.

* **When to stop:** Persistent LDL/TC rise attributable to betaine, intolerable GI symptoms, pregnancy planning without medical indication, or lack of any relevant goal (normal homocysteine, no training stimulus, no clinician-directed indication).


## Sourcing and Quality

* **Compound identity:** Look for **betaine anhydrous** or **trimethylglycine (TMG)** on the label—not betaine hydrochloride—unless the product is intentionally for digestion.
* **Dose transparency:** Prefer products stating milligrams of betaine anhydrous per serving without proprietary blends that hide the amount.
* **Third-party testing:** Choose brands with USP, NSF, Informed-Sport, or equivalent identity/purity testing where available; powder bulk should come from suppliers with certificates of analysis (heavy metals, microbial limits).
* **Formulation:** Capsules avoid taste issues; powders are cost-efficient for multi-gram use but are hygroscopic and can taste sweet-bitter. Avoid products that conflate beetroot nitrate blends with defined TMG doses unless both are quantified.
* **Prescription vs supplement:** Pharmaceutical betaine anhydrous for homocystinuria is a different regulatory path from dietary supplements; do not assume supplement-grade equivalence to prescription product for rare metabolic disease.
* **Reputable retail patterns:** Established supplement companies that disclose anhydrous form and lot testing are preferable to no-name high-dose powders without CoAs. Life Extension and similar long-standing manufacturers market TMG capsules/powders widely; selection should still rest on testing and labeling, not brand narrative alone.


## Practical Considerations

* **Time to effect:** Homocysteine changes can appear within days to weeks of consistent dosing. Strength outcomes in studies generally require at least 1–2 weeks plus progressive training. Lipid changes, if they occur, are assessed over 6–12 weeks.
* **Common pitfalls:** Confusing betaine HCl with TMG; using ≥4–6 g/day without lipid checks; expecting fat-loss or NASH reversal from betaine alone; combining many methyl donors at once; ignoring folate/B12 deficiency while chasing homocysteine with TMG only.
* **Regulatory status:** Sold as a dietary supplement in many jurisdictions; betaine anhydrous is also a prescription drug for specific genetic disorders. Marketing claims for curing cardiovascular disease or reversing aging are not established by outcomes evidence.
* **Cost and access:** Generally inexpensive relative to many longevity multi-supplement items; widely available as capsules or powder. Cost is rarely a barrier compared with NMN or specialty peptides.
* **Taste and adherence:** Powder adherence fails when taste is disliked—capsules improve consistency for ≤3 g/day.


## Interaction with Foundational Habits

* **Sleep:** Direction: generally none to indirect. Betaine is not a stimulant; sleep disruption reports are anecdotal and usually appear in multi-supplement stacks. Practical note: avoid introducing several methyl donors at night simultaneously if sleep is fragile.
* **Nutrition:** Direction: potentiating / pathway-linked. Adequate dietary choline (eggs, liver, soy, crucifers), folate, and B12 reduce exclusive dependence on supplemental betaine; high methionine animal-protein patterns can raise homocysteine production and increase methyl-donor demand. Beets, spinach, quinoa, and wheat bran supply food betaine but usually far less per day than multi-gram supplements. Practical note: fix frank B12/folate gaps before escalating TMG.
* **Exercise:** Direction: potentiating for strength outcomes. Meta-analytic strength benefits appear in trained or training populations; betaine is not a substitute for progressive resistance work. Practical note: pair 2–2.5 g/day protocols with lower-body strength programming if performance is the goal; stay hydrated.
* **Stress management:** Direction: indirect / none established. Homocysteine and cardiovascular risk interact with chronic stress behaviorally (sleep, diet, alcohol), but betaine is not an anxiolytic. Practical note: do not use TMG to “treat” stress-related symptoms.


## Monitoring Protocol & Defining Success

Baseline testing before elective use should establish homocysteine, a standard lipid panel, and B12/folate status (with methylmalonic acid if B12 is borderline). Optional context labs include high-sensitivity C-reactive protein, comprehensive metabolic panel (liver enzymes, kidney function), and, when relevant, body-composition measures that are not solely bioimpedance-dependent if hydration shifts are a concern.

Ongoing monitoring after a stable dose: recheck lipids and homocysteine at about 6–12 weeks, then every 6–12 months if continuing long term—or sooner after dose changes. Repeat B12/folate if diet is restrictive or symptoms of deficiency appear.

| Biomarker | Optimal Functional Range | Why Measure It? | Context/Notes |
|-----------|--------------------------|-----------------|---------------|
| Total homocysteine | Often targeted ~5–9 µmol/L in prevention-oriented practice; lab reference upper limits commonly ~12–15 µmol/L | Primary betaine-responsive methylation marker | Fasting preferred; interpret with B12/folate; large B-vitamin trials showed biomarker benefit ≠ guaranteed event reduction |
| LDL cholesterol | Functional goals often <100 mg/dL (<70 mg/dL in higher atherosclerotic cardiovascular disease (ASCVD) risk) | Detect betaine-associated LDL rise | Fasting lipid panel; compare to personal baseline 6–12 weeks after dose changes |
| Total cholesterol | Contextual with apolipoprotein B (apoB)/LDL; many aim <200 mg/dL conventionally | Captures TC rise seen in ≥4 g/day meta-analyses | Do not treat TC in isolation from LDL/apoB |
| Apolipoprotein B (apoB) | Often <90 mg/dL general; lower in high risk | Better particle-risk marker if lipids shift | Useful if TC/LDL rise on betaine |
| Vitamin B12 | Functional practice often prefers mid-upper reference (e.g., >400–500 pg/mL) | Avoid missing deficiency while lowering homocysteine via BHMT | Pair with methylmalonic acid (MMA) if symptomatic or borderline |
| Folate (serum or red blood cell (RBC)) | Within lab reference; RBC folate reflects longer-term status | Folate path works in parallel with betaine/BHMT | Correct deficiency rather than only adding TMG |
| Methylmalonic acid (MMA) | Within lab reference (method-specific) | Specific functional B12 marker | When B12 status unclear |
| Alanine aminotransferase (ALT) / aspartate aminotransferase (AST) | Within lab reference; functional focus on low-normal | Liver context if metabolic disease present | High-dose historical NASH protocols need clinician labs |
| eGFR / creatinine | eGFR ≥90 mL/min/1.73 m² typical ideal; manage if <60 | Renal handling and dosing caution | Recheck if using multi-gram doses |

Qualitative markers:

* Training performance: lower-body strength progression, session quality, jump or power metrics if those were goals
* GI comfort: stool frequency, nausea, bloating after dose changes
* Subjective energy/mood/sleep when stacked with other methyl donors
* Body-composition trends interpreted cautiously (hydration confounders)


## Emerging Research

* **Betaine for metabolic dysfunction–associated steatohepatitis (MASH):** [NCT07276204](https://clinicaltrials.gov/study/NCT07276204) — phase 2 placebo-controlled trial concept for serologically diagnosed MASH (planned n ≈ 70); could clarify whether modern metabolic-liver populations differ from the earlier negative NASH histology RCT.
* **Betaine and choline for metabolic health:** [NCT06758856](https://clinicaltrials.gov/study/NCT06758856) — completed study (n ≈ 34) on betaine and choline in obesity-related metabolic contexts; results may refine body-composition and metabolic-marker expectations.
* **Maternal betaine during lactation:** [NCT04633044](https://clinicaltrials.gov/study/NCT04633044) and related pharmacokinetic work ([NCT07243678](https://clinicaltrials.gov/study/NCT07243678)) — early-life nutrition and milk betaine transfer; relevant to safety boundaries rather than elective midlife longevity use.
* **Exercise-linked aging biology:** Preclinical and translational reports (including exercise-induced betaine signals and aging-model work summarized in recent narrative/systematic aging reviews) explore whether betaine partly mediates training benefits—still far from proven “exercise mimetic” status in humans ([Zawieja & Chmurzynska, 2025](https://pubmed.ncbi.nlm.nih.gov/39647584/)).
* **Performance meta-analysis refresh:** The 2024 chronic-supplementation meta-analysis ([Zawieja et al., 2024](https://pubmed.ncbi.nlm.nih.gov/39514262/)) strengthens the lower-body strength case; future trials with standardized training blocks and female enrollment could raise or lower confidence.
* **Body-composition conflict resolution:** Divergent meta-analyses ([Gao et al., 2019](https://pubmed.ncbi.nlm.nih.gov/31623137/) vs [Ashtary-Larky et al., 2022](https://pubmed.ncbi.nlm.nih.gov/34743773/)) need larger RCTs with gold-standard body-composition methods and hydration control.
* **Hard cardiovascular outcomes:** Homocysteine lowering remains biomarker-level; no large betaine-specific event-driven RCT exists. Observational work on circulating choline/betaine and CVD ([Yang et al., 2023](https://pubmed.ncbi.nlm.nih.gov/37318151/); [Meyer & Shea, 2017](https://pubmed.ncbi.nlm.nih.gov/28686188/)) continues to cut both ways depending on exposure definition (diet vs blood levels).
* **TMAO and microbiome:** Better human trials measuring TMAO after defined anhydrous betaine doses would either substantiate or retire a common safety objection.


## Conclusion

Betaine (trimethylglycine) is a methyl donor that also helps cells hold water under stress. Human trials show a clear, repeatable drop in blood homocysteine and a moderate signal for greater maximal strength—especially in the lower body—when use is paired with training. Those findings matter for longevity-oriented adults who track methylation-related labs and who treat muscle strength as a long-horizon healthspan asset. Evidence is much weaker for fat loss, broad anti-inflammatory effects, and fatty-liver tissue improvement: pooled body-composition studies disagree, inflammatory blood markers barely move, and a year-long high-dose randomized study in nonalcoholic fatty liver inflammation did not meet its main tissue-scoring goals.

On the risk side, stomach and gut intolerance is the main practical limiter at high intakes, and multi-gram dosing can raise total and low-density lipoprotein cholesterol enough that lipid monitoring is part of careful use. Theoretical concerns about a gut-liver metabolite (trimethylamine N-oxide) and aggressive multi-supplement methyl combinations remain incompletely tested. Overall evidence quality is strongest for lab markers and intermediate performance outcomes, not for hard cardiovascular or aging endpoints. For a proactive, risk-aware user, betaine is best understood as a targeted tool for homocysteine metabolism and training-supportive strength work—at modest doses, with labs—rather than as a general-purpose longevity remedy.

**[Top](#top) - [Benefits](#expected-benefits) - [Risks](#potential-risks--side-effects) - [Protocol](#therapeutic-protocol)**